Cowen analyst Yaron Werber initiates coverage on Stoke Therapeutics (NASDAQ: STOK) with a Outperform rating.The analyst comments "Stoke’s proprietary Targeted ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE